Reengineering translational science: the time is right
- PMID: 21734173
- PMCID: PMC5101940
- DOI: 10.1126/scitranslmed.3002747
Reengineering translational science: the time is right
Abstract
Despite dramatic advances in the molecular pathogenesis of disease, translation of basic biomedical research into safe and effective clinical applications remains a slow, expensive, and failure-prone endeavor. To pursue opportunities for disruptive translational innovation, the U.S. National Institutes of Health (NIH) intends to establish a new entity, the National Center for Advancing Translational Sciences (NCATS). The mission of NCATS is to catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of diseases and conditions. The new center's activities will complement, and not compete with, translational research being carried out at NIH and elsewhere in the public and private sectors.
References
-
- Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959–968. - PubMed
-
- Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: The pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010;9:203–214. - PubMed
-
- Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34–47. - PubMed
-
- Axelrod J, Whitby LG, Hertting G. Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues. Science. 1961;133:383–384. - PubMed
-
- Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586–600. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
